CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California

Yu-Jui Yvonne Wan, R. E. Poland, G. Ran, T. Konishi, Y. P. Zheng, K. M. Lin

Research output: Contribution to journalArticle

Abstract

Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001

Fingerprint

Cytochrome P-450 CYP2D6
African Americans
Enzymes
Genes
Alleles
Dextromethorphan
Disease Susceptibility
Genetic Polymorphisms
Healthy Volunteers
Genotype
Phenotype
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California. / Wan, Yu-Jui Yvonne; Poland, R. E.; Ran, G.; Konishi, T.; Zheng, Y. P.; Lin, K. M.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

Wan, Yu-Jui Yvonne ; Poland, R. E. ; Ran, G. ; Konishi, T. ; Zheng, Y. P. ; Lin, K. M. / CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 2.
@article{6ad520bbcd9241ad908a6d9cf26e2595,
title = "CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California",
abstract = "Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs {\%}Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.",
author = "Wan, {Yu-Jui Yvonne} and Poland, {R. E.} and G. Ran and T. Konishi and Zheng, {Y. P.} and Lin, {K. M.}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California

AU - Wan, Yu-Jui Yvonne

AU - Poland, R. E.

AU - Ran, G.

AU - Konishi, T.

AU - Zheng, Y. P.

AU - Lin, K. M.

PY - 2001

Y1 - 2001

N2 - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.

AB - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.

UR - http://www.scopus.com/inward/record.url?scp=33748966846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748966846&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748966846

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -